Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chiang, Kun Chun ^a,b   Yeh, Ta Sen ^a   Wu, Ren Chin ^a   Pang, Jong Hwei S ^c   Cheng, Chi Tung ^a   Wang, Shang Yu ^a   Juang, Horng Heng ^b,c   Yeh, Chun Nan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; NDRG2 PROTEIN, HUMAN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BILE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL MOTION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; GALLSTONE; GENETICS; HUMAN; METABOLISM; METASTASIS; MORTALITY; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; BILE; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINTS; GALLSTONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOCALIN-2; MICE; MICE, NUDE; NEOPLASM METASTASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

EID: 84992597793     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36138     Document Type: Article

References (52)

1. Khan, S. A. et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61, 1657-1669, doi: 10.1136/gutjnl-2011-301748 (2012).
2. Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet 383, 2168-2179, doi: 10.1016/S0140-6736(13)61903-0 (2014).
3. Flower, D. R. The lipocalin protein family: structure and function. Biochem J 318 (Pt 1), 1-14 (1996).
4. Yang, J. et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 10, 1045-1056 (2002).
5. Candido, S. et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 5, 1576-1594, doi: 10.18632/oncotarget.1738 (2014).
6. Bolignano, D. et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 288, 10-16, doi: 10.1016/j.canlet.2009.05.027 (2010).
7. Chakraborty, S., Kaur, S., Guha, S. & Batra, S. K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826, 129-169, doi: 10.1016/j.bbcan.2012.03.008 (2012).
8. Lim, R. et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 120, 2426-2434, doi: 10.1002/ijc.22352 (2007).
9. Tong, Z. et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 68, 6100-6108, doi: 10.1158/0008-5472.CAN-08-0540 (2008).
10. Lee, H. J. et al. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 118, 2490-2497, doi: 10.1002/ijc.21657 (2006).
11. Qu, X. et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 229, 35-44 (2002).
12. Zhou, R. H. et al. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73, 86-97, doi: 10.1006/geno.2000.6496 (2001).
13. Guan, R. J. et al. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 60, 749-755 (2000).
14. Bandyopadhyay, S. et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63, 1731-1736 (2003).
15. Ring, B. Z. et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24, 3039-3047, doi: 10.1200/JCO.2006.05.6564 (2006).
16. Tepel, M. et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123, 2080-2086, doi: 10.1002/ijc.23705 (2008).
17. Chiang, K. C. et al. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci Rep 5, 8686, doi: 10.1038/srep08686 (2015).
18. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890, doi: 10.1016/j.cell.2009.11.007 (2009).
19. Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940, doi: 10.1016/j.cell.2011.04.029 (2011).
20. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715, doi: 10.1016/j.cell.2008.03.027 (2008).
21. Polette, M. et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 13, 31-37 (1993).
22. Ueno, H. et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57, 2055-2060 (1997).
23. Chiang, K. C. et al. Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model. Oncotarget 5, 3849-3861, doi: 10.18632/oncotarget.2000 (2014).
24. Vermeulen, K., Van Bockstaele, D. R. & Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-149 (2003).
25. Powers, J. T. et al. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2, 203-214 (2004).
26. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi: 10.1016/j.cell.2011.02.013 (2011).
27. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7, 415-428, doi: 10.1038/nrc2131 (2007).
28. Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. J Cell Sci 121, 727-735, doi: 10.1242/jcs.000455 (2008).
29. Takeichi, M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 7, 619-627 (1995).
30. Wheelock, M. J. & Jensen, P. J. Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin. J Cell Biol 117, 415-425 (1992).
31. Birchmeier, W., Hulsken, J. & Behrens, J. Adherens junction proteins in tumour progression. Cancer Surv 24, 129-140 (1995).
32. Tsanou, E., Peschos, D., Batistatou, A., Charalabopoulos, A. & Charalabopoulos, K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 28, 3815-3826 (2008).
33. Baek, S. et al. CDH3/P-Cadherin regulates migration of HuCCT1 cholangiocarcinoma cells. Anat Cell Biol 43, 110-117, doi: 10.5115/acb.2010.43.2.110 (2010).
34. Yan, L., Borregaard, N., Kjeldsen, L. & Moses, M. A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276, 37258-37265, doi: 10.1074/jbc.M106089200 (2001).
35. Nuntagowat, C., Leelawat, K. & Tohtong, R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis 27, 295-305, doi: 10.1007/s10585-010-9327-y (2010).
36. Ellen, T. P., Ke, Q., Zhang, P. & Costa, M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29, 2-8, doi: 10.1093/carcin/bgm200 (2008).
37. Melotte, V. et al. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 24, 4153-4166, doi: 10.1096/fj.09-151464 (2010).
38. Kurdistani, S. K. et al. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58, 4439-4444 (1998).
39. Salnikow, K., Su, W., Blagosklonny, M. V. & Costa, M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res 60, 3375-3378 (2000).
40. Liu, J. et al. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 316, 1985-1993, doi: 10.1016/j.yexcr.2010.02.028 (2010).
41. Tao, Y. et al. AKT inhibitor suppresses hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells. Braz J Med Biol Res 46, 394-404 (2013).
42. Candido, S. et al. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumour Biol, doi: 10.1007/s13277-016-4872-x (2016).
43. Zabron, A. A. et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol 106, 1711-1717, doi: 10.1038/ajg.2011.187 (2011).
44. Candido, S. et al. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta 1863, 438-448, doi: 10.1016/j.bbamcr.2015.08.010 (2016).
45. Bauer, M. et al. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108, 389-397, doi: 10.1007/s10549-007-9619-3 (2008).
46. Wang, H. J. et al. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken) 293, 1855-1863, doi: 10.1002/ar.21230 (2010).
47. Chiang, K. C. et al. 19-Nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxy vitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids 76, 1513-1519, doi: 10.1016/j.steroids.2011.08.006 (2011).
48. Ouyang, W. et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arseniteinduced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 65, 9287-9293, doi: 65/20/9287 [pii] 10.1158/0008-5472.CAN-05-0469 (2005).
49. Tsui, K. H., Chung, L. C., Feng, T. H., Chang, P. L. & Juang, H. H. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell prolifertation and cell invasion in prostate carcinoma cells. Int J Cancer, doi: 10.1002/ijc.26284 (2011).
50. Chiang, K. C. et al. MART-10, a less calcemic vitamin D analog, is more potent than 1alpha,25-dihydroxy vitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. J Steroid Biochem Mol Biol 139, 54-60, doi: 10.1016/j.jsbmb.2013.10.005 (2014).
51. Tsui, K. H. et al. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci Rep 5, 12870, doi: 10.1038/srep12870 (2015).
52. Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32-35 (1950).